Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

News Release

Wave Life Sciences to Present at Upcoming Investor Conferences

April 5, 2018 at 4:41 PM EDT

CAMBRIDGE, Mass., April 05, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, will be participating at the following conferences:

H.C. Wainwright & Co. Global Life Sciences Conference
April 9th at 9:00 a.m. CEST – Monte Carlo, Monaco

Leerink Partners’ CNS Day
April 18th at 10:00 a.m. EST – New York, NY
 

About Wave Life Sciences

Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. For more information, please visit www.wavelifesciences.com.

Investor Contact:

Jillian Connell
617-949-2981
jconnell@wavelifesci.com

Media Contact:

Jose Juves
617-949-4708
jjuves@wavelifesci.com

Primary Logo

Source: Wave Life Sciences